![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novo Nordisk Launches Cheaper Insulin Options
Novo Nordisk Launches Cheaper Insulin Options
![Novo-Nordisk.gif](https://www.fdanews.com/ext/resources/test/Drug-Images2/Novo-Nordisk.gif?t=1578614749&width=430)
January 9, 2020
Novo Nordisk launched half-priced generic versions of NovoLog and NovoLog Mix in the U.S., aiming to provide cheaper insulin products.
The generic of NovoLog (insulin aspart) will cost $144.68 per vial, and $279.41 for a pack of five. The lower-cost version of NovoLog Mix (insulin aspart mix 70/30) will cost $150.06 per vial, and a pack of five vials will cost $279.41.
In addition, the drugmaker launched its My$99Insulin program, a cash card program that allows diabetes patients to receive up to three vials or two packs of FlexPen/FlexTouch of any combination of Novo Nordisk insulin for $99.
Upcoming Events
-
21Oct